123 related articles for article (PubMed ID: 31380285)
21. Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].
Dent P; Booth L; Poklepovic A; Hoff DV; Hancock JF
Cell Signal; 2020 Apr; 68():109525. PubMed ID: 31911180
[TBL] [Abstract][Full Text] [Related]
22. GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.
Booth L; Roberts JL; West C; Dent P
Oncotarget; 2024 Mar; 15():159-174. PubMed ID: 38441437
[TBL] [Abstract][Full Text] [Related]
23. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.
Tavallai M; Booth L; Roberts JL; Poklepovic A; Dent P
Front Oncol; 2016; 6():142. PubMed ID: 27379204
[TBL] [Abstract][Full Text] [Related]
24. Valproate augments Niraparib killing of tumor cells.
Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
[TBL] [Abstract][Full Text] [Related]
25. Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
Tavallai S; Hamed HA; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2014 May; 15(5):578-85. PubMed ID: 24556916
[TBL] [Abstract][Full Text] [Related]
26. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
[TBL] [Abstract][Full Text] [Related]
27. [Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.
Booth L; Roberts JL; Rais R; Kirkwood J; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Oncotarget; 2018 Jan; 9(5):6062-6074. PubMed ID: 29464055
[TBL] [Abstract][Full Text] [Related]
28. GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling.
Booth L; West C; Hoff DV; Dent P
Front Oncol; 2020; 10():1331. PubMed ID: 32983965
[TBL] [Abstract][Full Text] [Related]
29. (Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.
Dent P; Booth L; Roberts JL; Poklepovic A; Hancock JF
J Cell Physiol; 2020 Oct; 235(10):6862-6874. PubMed ID: 31985048
[TBL] [Abstract][Full Text] [Related]
30. GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells.
Booth L; West C; Von Hoff D; Kirkwood JM; Dent P
Front Oncol; 2021; 11():656453. PubMed ID: 33898322
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43.
Dent P; Booth L; Roberts JL; Poklepovic A; Cridebring D; Reiman EM
Aging (Albany NY); 2021 Jul; 13(13):17097-17117. PubMed ID: 34252884
[TBL] [Abstract][Full Text] [Related]
32. GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins.
Booth L; West C; Moore RP; Von Hoff D; Dent P
Front Oncol; 2021; 11():711043. PubMed ID: 34490108
[TBL] [Abstract][Full Text] [Related]
33. Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function.
Booth L; Shuch B; Albers T; Roberts JL; Tavallai M; Proniuk S; Zukiwski A; Wang D; Chen CS; Bottaro D; Ecroyd H; Lebedyeva IO; Dent P
Oncotarget; 2016 Mar; 7(11):12975-96. PubMed ID: 26887051
[TBL] [Abstract][Full Text] [Related]
34. NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.
Booth L; Roberts JL; Poklepovic A; Dent P
Oncol Signal; 2018 Jun; 1(1):19-30. PubMed ID: 30740589
[TBL] [Abstract][Full Text] [Related]
35. Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species.
Roberts JL; Poklepovic A; Booth L
Oncotarget; 2017 Nov; 8(59):99451-99469. PubMed ID: 29245915
[TBL] [Abstract][Full Text] [Related]
36. GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.
Booth MR; Booth L; Roberts JL; West C; Dent P
Oncotarget; 2024 Feb; 15():124-133. PubMed ID: 38329728
[TBL] [Abstract][Full Text] [Related]
37. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Dembla V; Groisberg R; Hess K; Fu S; Wheler J; Hong DS; Janku F; Zinner R; Piha-Paul SA; Ravi V; Benjamin RS; Patel S; Somaiah N; Herzog CE; Karp DD; Roszik J; Meric-Bernstam F; Subbiah V
Sci Rep; 2017 Nov; 7(1):15963. PubMed ID: 29162825
[TBL] [Abstract][Full Text] [Related]
39. Fingolimod Augments Monomethylfumarate Killing of GBM Cells.
Dent P; Booth L; Roberts JL; Poklepovic A; Hancock JF
Front Oncol; 2020; 10():22. PubMed ID: 32047722
[TBL] [Abstract][Full Text] [Related]
40. Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.
Yokoyama N; Matsunobu T; Matsumoto Y; Fukushi JI; Endo M; Hatano M; Nabeshima A; Fukushima S; Okada S; Iwamoto Y
Sci Rep; 2017 Mar; 7():45332. PubMed ID: 28350009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]